Literature DB >> 17142106

Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression.

Dan Turner1, Catharine M Walsh, A Hillary Steinhart, Anne M Griffiths.   

Abstract

BACKGROUND & AIMS: Colectomy is a potentially life-saving procedure for patients with severe attacks of UC who fail medical therapy. We aimed to systematically review studies that reported the short-term colectomy rate in severe UC or reported variables that could predict treatment failure.
METHODS: We conducted a systematic literature search for cohort studies and controlled trials published between 1974-2006.
RESULTS: Thirty-two studies met the inclusion criteria; 16 reported short-term outcome and predictors of therapy failure, 13 only outcome, and 3 only predictors. In the pooled analysis, 581 of 1991 patients required colectomy (weighted mean 27; 95% confidence interval [CI], 26%-28%), and 22 died (1%; 95% CI, 0.7%-1.5%). In a heterogeneity-controlled meta-regression, colectomy rate did not change during the last 30 years (R(2) = 0.07, P = .8). Cyclosporine was used in only 100 patients, with a 51% (95% CI, 41%-60%) short-term success rate. A second meta-regression failed to demonstrate a dose-colectomy response of methylprednisolone therapy beyond 60 mg daily (R(2) < 0.01, P = .98). More than 20 variables were identified in 19 studies to predict medical therapy failure, but only a few were consistently reproduced: disease extent, stool frequency, temperature, heart rate, C-reactive protein, albumin, and radiologic assessment.
CONCLUSIONS: The short-term colectomy rate in severe UC has remained stable during the last 30 years, despite the introduction of cyclosporine, which was not used frequently. We could not find any support for administering methylprednisolone at a higher dose than 60 mg/day. Variables that predict outcome of corticosteroid therapy could aid in the development of guidelines for introduction of rescue therapies in severe UC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142106     DOI: 10.1016/j.cgh.2006.09.033

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  122 in total

1.  A Practical Clinical Approach to the Management of High-Risk Ulcerative Colitis.

Authors:  David T Rubin; Cindy Traboulsi; Victoria Rai
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-02

2.  A think tank of the Italian Society of Colorectal Surgery (SICCR) on the surgical treatment of inflammatory bowel disease using the Delphi method: ulcerative colitis.

Authors:  F Selvaggi; G Pellino; G Ghezzi; D Corona; G Riegler; G G Delaini
Journal:  Tech Coloproctol       Date:  2015-09-19       Impact factor: 3.781

3.  Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.

Authors:  Sameer D Saini; Akbar K Waljee; Peter D R Higgins
Journal:  Clin Gastroenterol Hepatol       Date:  2012-05-18       Impact factor: 11.382

4.  Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis.

Authors:  Amar Vedamurthy; Louise Xu; Jay Luther; Francis Colizzo; John J Garber; Hamed Khalili; Ashwin N Ananthakrishnan
Journal:  Dig Dis Sci       Date:  2018-06-27       Impact factor: 3.199

5.  Serum Procalcitonin as a Potential Early Predictor of Short-Term Outcomes in Acute Severe Ulcerative Colitis.

Authors:  Hui-Min Wu; Juan Wei; Jin Li; Kai Wang; Lei Ye; Ying Qi; Bo-Si Yuan; Yu-Lin Yang; Li Zhao; Zhao Yang; Miao-Fang Yang; Jian-Feng Gong; Fang-Yu Wang
Journal:  Dig Dis Sci       Date:  2019-01-02       Impact factor: 3.199

6.  Branched Fatty Acid Esters of Hydroxy Fatty Acids (FAHFAs) Protect against Colitis by Regulating Gut Innate and Adaptive Immune Responses.

Authors:  Jennifer Lee; Pedro M Moraes-Vieira; Angela Castoldi; Pratik Aryal; Eric U Yee; Christopher Vickers; Oren Parnas; Cynthia J Donaldson; Alan Saghatelian; Barbara B Kahn
Journal:  J Biol Chem       Date:  2016-08-29       Impact factor: 5.157

Review 7.  MANAGEMENT OF ACUTE SEVERE ULCERATIVE COLITIS: A CLINICAL UPDATE.

Authors:  Carlos Walter Sobrado; Lucas Faraco Sobrado
Journal:  Arq Bras Cir Dig       Date:  2016 Jul-Sep

Review 8.  Severe ulcerative colitis: at what point should we define resistance to steroids?

Authors:  Maria Esteve; Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2008-09-28       Impact factor: 5.742

9.  Efficacy of Induction Therapy With High-Intensity Tofacitinib in 4 Patients With Acute Severe Ulcerative Colitis.

Authors:  Jeffrey A Berinstein; Calen A Steiner; Randolph E Regal; John I Allen; Jami A R Kinnucan; Ryan W Stidham; Akbar K Waljee; Shrinivas Bishu; Leslie B Aldrich; Peter D R Higgins
Journal:  Clin Gastroenterol Hepatol       Date:  2018-11-17       Impact factor: 11.382

Review 10.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.